Indication

Hemophagocytic lymphohistiocytosis

Hemophagocytic lymphohistiocytosis is a rare, life-threatening hyperinflammatory syndrome characterized by severe immune dysregulation and uncontrolled activation of cytotoxic T lymphocytes, natural killer cells, and macrophages. Read more about Hemophagocytic lymphohistiocytosis

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Hemophagocytic lymphohistiocytosis therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Hemophagocytic lymphohistiocytosis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hemophagocytic lymphohistiocytosis.

Hemophagocytic lymphohistiocytosis is a rare, life-threatening hyperinflammatory syndrome characterized by severe immune dysregulation and uncontrolled activation of cytotoxic T lymphocytes, natural killer cells, and macrophages.

The condition can affect individuals of any age, presenting either as a primary inherited disorder typically emerging in infancy or early childhood, or as an acquired secondary syndrome in older children and adults triggered by severe infections, malignancies, or autoimmune diseases.

Pathophysiologically, the failure of normal cytotoxic down-regulation leads to hypercytokinemia, excessive tissue infiltration, and hemophagocytosis across the reticuloendothelial and hematologic systems.

Hallmark clinical features include persistent high fevers, hepatosplenomegaly, progressive cytopenias, marked hyperferritinemia, hypofibrinogenemia, and rapid progression toward multiorgan dysfunction.

Personalize your experience

Follow Hemophagocytic lymphohistiocytosis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it